Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2023-11-18
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability,
pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate
safety and anti- tumor activity of Q702 administered orally.